Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pope, W. B.
Right arrow Articles by Cloughesy, T. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pope, W. B.
Right arrow Articles by Cloughesy, T. F.
Related Collections
Right arrow MRI
Right arrow All Oncology
Right arrow Primary brain tumor
Right arrow Chemotherapy-tumor
NEUROLOGY 2006;66:1258-1260
© 2006 American Academy of Neurology
Brief Communications

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy

W. B. Pope, MD, PhD, A. Lai, MD, PhD, P. Nghiemphu, MD, P. Mischel, MD and T. F. Cloughesy, MD

From the Departments of Radiological Sciences (W.B.P.), Neurology (A.L., P.N., T.F.C.), and Pathology and Laboratory Medicine (P.M.), David Geffen School of Medicine at UCLA, Los Angeles, CA.

Address correspondence and reprint requests to Dr. Whitney B. Pope, Department of Radiological Sciences, David Geffen School of Medicine at UCLA Medical Center, 10833 Le Conte Avenue, BL-428/CHS, Los Angeles, CA 90095-1721; e-mail: wpope{at}mednet.ucla.edu

Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.

Disclosure: The authors report no conflicts of interest.

Received October 4, 2005. Accepted in final form January 13, 2006.




This article has been cited by other articles:


Home page
 NeurologyHome page
A. D. Norden, G. S. Young, K. Setayesh, A. Muzikansky, R. Klufas, G. L. Ross, A. S. Ciampa, L. G. Ebbeling, B. Levy, J. Drappatz, et al.
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Neurology, March 4, 2008; 70(10): 779 - 787.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
J.W. Henson, S. Ulmer, and G.J. Harris
Brain Tumor Imaging in Clinical Trials
AJNR Am. J. Neuroradiol., March 1, 2008; 29(3): 419 - 424.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Chamberlain
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma
J. Clin. Oncol., February 20, 2008; 26(6): 1012 - 1013.
[Full Text] [PDF]

Home page
 JCOHome page
S. Sathornsumetee, Y. Cao, J. E. Marcello, J. E. Herndon II, R. E. McLendon, A. Desjardins, H. S. Friedman, M. W. Dewhirst, J. J. Vredenburgh, and J. N. Rich
Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan
J. Clin. Oncol., January 10, 2008; 26(2): 271 - 278.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
P. Nghiemphu, R. M. Green, W. B. Pope, A. Lai, and T. F. Cloughesy
Safety of anticoagulation use and bevacizumab in patients with glioma
Neuro-oncol, January 1, 2008; 10(3): 355 - 360.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Chen, S. Delaloye, D. H.S. Silverman, C. Geist, J. Czernin, J. Sayre, N. Satyamurthy, W. Pope, A. Lai, M. E. Phelps, et al.
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
J. Clin. Oncol., October 20, 2007; 25(30): 4714 - 4721.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Duda, R. K. Jain, and C. G. Willett
Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers
J. Clin. Oncol., September 10, 2007; 25(26): 4033 - 4042.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. R.J. Carlson, W. B. Pope, S. Horvath, J. G. Braunstein, P. Nghiemphu, C.-L. Tso, I. Mellinghoff, A. Lai, L. M. Liau, P. S. Mischel, et al.
Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2
Clin. Cancer Res., May 1, 2007; 13(9): 2592 - 2598.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Chamberlain, W. B. Pope, and T. Cloughesy
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Neurology, December 12, 2006; 67(11): 2089 - 2089.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Marc C. Chamberlain
Neurology Online, 21 Jun 2006 [Full text]
Reply from the authors
Whitney B Pope, MD, PhD, et al.
Neurology Online, 21 Jun 2006 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.